Meredith A Hackel (Meredith Hackel)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 18

Top Topics

Acinetobacter Baumannii

Multidrug Resistant

Urinary Tract Infection

Quality Control

Top Venues

Antimicrobial agents and chemotherapy

Journal of clinical microbiology

This page only lists publications with an associated author ORCID identifier.

Publications

James A Karlowsky, Meredith A Hackel, Gregory G Stone, Daniel F Sahm
In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrobial agents and chemotherapy 67 (1) (2023)
James A Karlowsky, Meredith A Hackel, Gregory G Stone, Daniel F Sahm
In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrobial agents and chemotherapy 67 (1) (2023)
Edith Csiki-Fejer, Maria Traczewski, Gary W Procop, Thomas E Davis, Meredith A Hackel, Hari P Dwivedi, David H Pincus
Multicenter Clinical Performance Evaluation of Omadacycline Susceptibility Testing of Enterobacterales on VITEK 2 Systems. Journal of clinical microbiology (2023)
James A Karlowsky, Meredith A Hackel, Gregory G Stone, Daniel F Sahm
In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrobial agents and chemotherapy 67 (1) (2023)
James A Karlowsky, Meredith A Hackel, Miki Takemura, Yoshinori Yamano, Roger Echols, Daniel F Sahm
Erratum for Karlowsky et al., " In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019". Antimicrobial agents and chemotherapy (2023)
James A Karlowsky, Meredith A Hackel, Gregory G Stone, Daniel F Sahm
In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrobial agents and chemotherapy (2023)
James A Karlowsky, Meredith A Hackel, Gregory G Stone, Daniel F Sahm
In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrobial agents and chemotherapy 67 (1) (2023)
Miki Takemura, Rio Nakamura, Merime Ota, Ryuichiro Nakai, Daniel F Sahm, Meredith A Hackel, Yoshinori Yamano
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. Antimicrobial agents and chemotherapy (2023)
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy 67 (1) (2022)
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy 67 (1) (2022)
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy 67 (1) (2022)
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy 67 (1) (2022)
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy (2022)
James A Karlowsky, Meredith A Hackel, Sarah M McLeod, Alita A Miller
In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii - calcoaceticus Complex Collected from 2016 to 2021. Antimicrobial agents and chemotherapy 66 (9) (2022)
James A Karlowsky, Meredith A Hackel, Daniel F Sahm
In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales. Antimicrobial agents and chemotherapy (2021)
James A Karlowsky, Meredith A Hackel, Miki Takemura, Yoshinori Yamano, Echols Roger, Daniel F Sahm
In Vitro Susceptibility of Gram-negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies (2014-2019). Antimicrobial agents and chemotherapy (2021)
Meredith A Hackel, James A Karlowsky, Michele A Canino, Daniel F Sahm, Nicole E Scangarella-Oman
In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes. Antimicrobial agents and chemotherapy 66 (2) (2021)
James A Karlowsky, Meredith A Hackel, Samuel K Bouchillon, Daniel F Sahm
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems. Antimicrobial agents and chemotherapy 64 (12) (2020)